University Of Sydney

University Of Sydney, doing business as International Clinical Trials Symposium, is an Australian international educational institution that acts as a prime recipient on federal research grants and contracts across defense, health, and scientific domains, with a footprint spanning basic research in quantum computing, vaccine immunology, biomedical development, and clinical trial execution. The institution competes predominantly in full-and-open procurements without set-aside designations; all prime contracts and grants in the source record are unrestricted.

The vendor's customer concentration reflects fragmentation across the National Institutes of Health and the Department of the Air Force. The National Institute of Allergy and Infectious Diseases leads in combined potential value with 12 awards worth $14.1 million, anchored by a $14.1 million definitive contract for advancing vaccine adjuvant research for tuberculosis (awarded September 30, 2022, ultimate completion September 29, 2027, cost no-fee pricing). The Food and Drug Administration has placed two awards totaling $1.9 million potential value: a $687 thousand firm fixed-price contract for development of a laser-based testing platform for generic dry powders (awarded September 21, 2023, completion September 20, 2025) and a $1.2 million contract for improving scientific approaches to evaluate generic drugs (awarded September 27, 2022, completion September 29, 2026). The Department of the Air Force appears across 26 awards and the National Cancer Institute across 12 awards, though dollar magnitudes for Air Force and NCI awards are not separately itemized in the source. The Army's Research Development and Engineering Command has funded eight awards with $444 thousand combined potential value, including a $150 thousand firm fixed-price contract for autonomous underwater vehicle research and development (awarded January 1, 2026, completion December 31, 2026, placed through a Broad Agency Announcement issued by Pacific Air Forces).

On the grant side, University of Sydney acts as prime recipient on project grants from the Office of Naval Research (quantum technologies, photonics, trapped-ion systems), the Air Force (quantum feedback networks, topological photonics, quantum information processing), the Defense Health Agency (bone marrow failure prevention, melanoma survival factors, postoperative delirium mitigation, musculoskeletal pain and sleep), the National Institute on Drug Abuse (substance use disorder neurobiology), the National Cancer Institute (prostate cancer genomics and health disparity), and the National Institute of Allergy and Infectious Diseases (HIV control mechanisms, adjuvant immunology). Representative grants include a $736,873 NIAID award (CFDA 93.855, ultimate completion June 30, 2031) for mechanism of action of MPL-QS21 adjuvant combination; a $632 thousand Defense Health Agency award (CFDA 12.420, completion June 30, 2028) investigating survival factors among women with melanoma; and a $1.4 million Defense Health Agency award for comparative effectiveness of exercise and cognitive behavioral therapy for chronic musculoskeletal pain and poor sleep (completion September 29, 2028).

The source does not identify a parent contract vehicle, IDIQ, GWAC, or BPA through which University of Sydney places task orders. Prime contract awards are definitive contracts awarded through agency solicitations or Broad Agency Announcements.

Activity has accelerated from 7 awards in 2022 to a peak of 29 awards in 2024, with 14 awards in 2025 and 7 in the first nine months of 2026 — a trajectory reflecting increased grant funding pipeline. Thirteen awards (combined potential value $14.3 million) reach ultimate completion in the next twenty-four months and face recompete exposure, primarily grants approaching the end of their three-to-five-year performance periods.

University of Sydney operates predominantly as a prime (69% of 152 awards), with 31% routed through sub awards to other prime recipients. Across SCI-reportable service contracts, the vendor invoiced $2.2 million in FY2024 and $3.2 million in FY2025, with government-paid hourly rates clustering around a median of $112.21/hr. In FY2024, the institution deployed 12.4 FTEs on SCI-reportable contracts; FY2025 shows 11.2 FTEs with rising hourly rates ($137.90/hr average, reflecting cost escalation). Subcontractors performed 9% of contractor hours across prime SCI contracts, with 10 named subcontractors noted. As a sub-recipient, University of Sydney has participated in grant work sponsored by Yale University (DARPA HEALR — molecular structure optimization), Washington University (postoperative delirium clinical trial execution in Australia), University of Wisconsin System (EEG and biomarker analysis), Harvard College (cervical cancer screening modeling via the Daffodil Centre), Johns Hopkins University (ADVISE clinical trial site conduct), and multiple other academic and medical center primes conducting NIH-funded research.

The institution's capabilities center on hypothesis-driven research execution in quantum information sciences, vaccine immunology and adjuvant mechanisms, cancer genomics and health disparities, postoperative and neurological dysfunction, substance use disorder neurobiology, and clinical trial conduct. Place of performance is Australia (Camperdown, New South Wales campus), with work performed under standard federal cost principles (2 CFR 200) and applicable DoD grants and agreements regulations. The vendor carries no federal contract ceiling vehicles, GWACs, or schedule positions in the source material.